Markets:

Overview

News

Currencies

International

Treasuries

Entrada Therapeutics, Inc. - Common Stock (NQ:TRDA)

7.270 +0.270 (+3.86%)

Streaming Delayed Price Updated: 4:00 PM EDT, Aug 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Entrada Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >

Entrada Therapeutics DMD Trial Shows Early Functional Gains, Clean Safety Profile ↗

May 09, 2026

Entrada Therapeutics (NASDAQ:TRDA) said initial data from the first cohort of its phase I/II ELEVATE-44-201 trial showed favorable safety and tolerability and early functional improvement in ambulatory...

Via MarketBeat

Which stocks are experiencing notable movement on Thursday? ↗

May 07, 2026

Via Chartmill

Top stock movements in today's session. ↗

May 07, 2026

Via Chartmill

There are notable gap-ups and gap-downs in today's session. ↗

May 07, 2026

Via Chartmill

Entrada Therapeutics (NASDAQ:TRDA) Plunges Nearly 48% as Early-Stage DMD Clinical Data Disappoints on Drug Exposure ↗

May 07, 2026

Via Chartmill

Beyond The Numbers: 4 Analysts Discuss Entrada Therapeutics Stock ↗

November 06, 2024

Via Benzinga

Recap: Entrada Therapeutics Q4 Earnings ↗

March 13, 2024

Via Benzinga

Which stocks are moving before the opening bell on Thursday? ↗

May 07, 2026

Via Chartmill

Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit ↗

March 18, 2026

Clinical-stage biotech Dianthus Therapeutics develops antibody therapies for severe autoimmune and neuromuscular conditions.

Via The Motley Fool

Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million Exit ↗

March 18, 2026

This Boston-based biotech develops therapies for neurological disorders, with a pipeline targeting depression, tremor, and rare epilepsies.

Via The Motley Fool

What One Fund's Sale of Centessa Stock Signals About the Fast-Rising Biotech Company ↗

November 29, 2025

Here's why a fast-rising pharmaceutical trimmed—and not abandoned—by a specialist fund signals ongoing conviction in the stock.

Via The Motley Fool

Topics Regulatory Compliance

5AM Venture Just Dumped Its Viking Stake—Smart Call or Missed Opportunity? ↗

November 18, 2025

One major biotech investor just walked away from Viking Therapeutics. Here’s what the move may—and may not—mean for the company’s clinical-stage future.

Via The Motley Fool

Topics Regulatory Compliance

5AM Venture Bails on MoonLake After a Brutal Year: Here’s What Stands Out ↗

November 18, 2025

A major biotech investor just walked away from MoonLake after a rough year for the stock. Here’s what that move signals—and what long-term investors should keep an eye on next.

Via The Motley Fool

Entrada (TRDA) Q2 Revenue Drops 98% ↗

August 06, 2025

Via The Motley Fool

Topics Intellectual Property

Entrada Therapeutics Inc (NASDAQ:TRDA) Reports Q2 2025 Earnings Miss, Shares Drop in Pre-Market Trading ↗

August 06, 2025

Entrada Therapeutics (TRDA) missed Q2 2025 revenue and EPS estimates, posting $1.95M revenue vs. $9.84M expected and a $1.04 loss per share. Shares fell 2% pre-market amid investor concerns. Pipeline...

Via Chartmill

Topics Earnings

FDA Clears Entrada Therapeutics' Early-Stage For Potential Treatment Of Duchenne Muscular Dystrophy ↗

February 24, 2025

Entrada Therapeutics gains FDA clearance for its Phase 1b ELEVATE-44-102 study, evaluating ENTR-601-44 in adult Duchenne muscular dystrophy patients.

Via Benzinga

TRDA Stock Earnings: Entrada Therapeutics Beats EPS, Beats Revenue for Q2 2024 ↗

August 13, 2024

TRDA stock results show that Entrada Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Via InvestorPlace

TRDA Stock Earnings: Entrada Therapeutics Beats EPS, Beats Revenue for Q1 2024 ↗

May 07, 2024

TRDA stock results show that Entrada Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Via InvestorPlace

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

April 11, 2024

Via Benzinga

Insiders Buying America's Car-Mart And 2 Other Stocks ↗

April 11, 2024

Although U.S. stocks closed lower on Wednesday, there were a few notable insider trades.

Via Benzinga

Around $5M Bet On This Communication Services Stock? Check Out These 4 Stocks Insiders Are Buying ↗

March 22, 2024

Although U.S. stocks closed higher on Thursday, there were a few notable insider trades.

Via Benzinga

HC Wainwright & Co. Maintains Buy Rating for Entrada Therapeutics: Here's What You Need To Know ↗

November 27, 2023

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

November 23, 2023

Via Benzinga

Why Is Neuromuscular Disease Focused Entrada Therapeutics Shares Trading Lower Today? ↗

November 22, 2023

Entrada Therapeutics Inc (NASDAQ: TRDA) shares are trading lower after the company announced updates on ENTR-601-44 in

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

November 22, 2023

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

June 26, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 3, 2023 ↗

April 03, 2023

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

March 09, 2023

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

February 16, 2023

Via Benzinga

Why Sabre Are Trading Lower By 19%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

February 15, 2023

Gainers Sera Prognostics, Inc. (NASDAQ: SERA) shares surged 63.4% to $2.11 after the company announced top-line data from the AVERT PRETERM TRIAL.

Via Benzinga

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.